Table 4:
Univariate Outcomes for Progression (n=102)
| Risk Factor | n | HR | 95% CI | P |
|---|---|---|---|---|
| Institution | ||||
| MDACC | 72 | Ref. | ||
| OHSU | 21 | 0.8 | 0.4–1.6 | 0.5 |
| Singapore | 9 | 0.6 | 0.3–1.4 | 0.3 |
| MDACC vs other | 1.4 | 0.8–2.5 | 0.3 | |
| ALL type | ||||
| Early | 28 | Ref. | ||
| Mature | 17 | 2.3 | 1.01–5.2 | 0.05 |
| Cortical | 27 | 1.5 | 0.7–3.3 | 0.3 |
| ETP | 16 | 1.2 | 0.5–2.6 | 0.7 |
| Unknown | 14 | Excluded | ||
| Age | ||||
| <18 | 11 | Ref. | ||
| 18–39 | 63 | 1 | 0.4–2.4 | 0.9 |
| >=40 | 28 | 0.9 | 0.3–2.4 | 0.8 |
| Sex | ||||
| Male | 77 | Ref. | ||
| Female | 25 | 0.65 | 0.3–1.2 | 0.2 |
| Disease Status at Transplant | ||||
| CR1 | 38 | Ref. | ||
| CR2 | 40 | 1.8 | 0.8–3.7 | 0.09 |
| PIF/CR1 | 6 | 3.7 | 1.4–9.6 | 0.008 |
| Not CR | 18 | 4.9 | 2.1–11 | <0.001 |
| WBC | ||||
| >100K | 63 | Ref. | ||
| <=100K | 18 | 1.2 | 0.6–2.3 | 0.6 |
| Unknown | 21 | Excluded | ||
| Extra-medullary disease | ||||
| No | 46 | Ref. | ||
| Yes | 56 | 1.7 | 0.98–2.9 | 0.06 |
| CNS disease | ||||
| Yes | 11 | Ref. | ||
| No | 90 | 2.15 | 0.97–4.8 | 0.06 |
| Unknown | 1 | Excluded | ||
| MRD at Transplant after 2004 (N=84) | ||||
| Yes | 18 | 2.6 | 1.3–5.4 | 0.007 |
| No | 46 | Ref | ||
| Unknown | 6 | Excluded | ||
| Stem Cell source | ||||
| PB | 60 | Ref. | ||
| BM | 27 | 0.99 | 0.5–1.9 | 0.97 |
| CBT | 15 | 0.7 | 0.3–1.5 | 0.3 |
| Donor Type | ||||
| MRD | 43 | Ref. | ||
| MUD | 36 | 0.9 | 0.5–1.6 | 0.7 |
| Other | 23 | 0.5 | 0.2–1.1 | 0.08 |
| Prep | ||||
| Ablative | 79 | Ref. | ||
| RIC | 16 | 1.5 | 0.7–3.0 | 0.3 |
| NMA | 7 | 0.8 | 0.2–2.5 | 0.6 |
| ATG | ||||
| Yes | 24 | 0.68 | 0.34–1.36 | 0.28 |
| No | 78 | Ref | ||
| TBI >2 Gy | ||||
| Yes | 42 | 1.02 | 0.6–1.7 | 0.9 |
| No | 60 | Ref. | ||
| HCT-CI | ||||
| 0–2 | 60 | Ref. | ||
| >=3 | 30 | 1.2 | 0.7–2.2 | 0.5 |
| Unknown | 12 | Excluded | ||
| Cytogenetics | ||||
| High / v High | 14 | Ref. | ||
| Intermediate | 66 | 1 | 0.5–2.1 | 0.9 |
| Unknown | 22 | Excluded |
Given MRD measurement for MRD in ALL became standard in 2004, only patients transplanted after 2004 were analyzed in the multivariate analysis for progression (n=84). Disease status and MRD were prognostic factors for progression.
Abbreviations: CR:complete remission; PIF/CR1: patients with primary induction failure who eventually achieved first CR; WBC: White Blood Count; CNS: Central nervous system; MRD: minimal residual disease; PB: peripheral blood; BM: bone marrow; CBT: cord blood transplant; ATG: anti-thymocyte globulin, TBI: total body irradiation, HCT-CI: Hematopoietic cell transplantation-comorbidity index